<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156949</url>
  </required_header>
  <id_info>
    <org_study_id>20040268</org_study_id>
    <nct_id>NCT00156949</nct_id>
  </id_info>
  <brief_title>EPO Deep Tank in Dialysis Subjects</brief_title>
  <official_title>An Open-Label, Single-Arm Study to Assess the Safety of Epoetin Alfa Manufactured by a Deep Tank Technology in Subjects With Chronic Kidney Disease Receiving Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      Subject incidence of adverse events
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine whether Epoetin alfa manufactured by a roller bottle technology (Epoetin alfa
      RB) and Epoetin alfa manufactured by a deep tank process (Epoetin alfa DT) have comparable
      safety profiles when administered to patients with CKD receiving dialysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">580</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Epoetin alfa DT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa DT</intervention_name>
    <description>Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL</description>
    <arm_group_label>Epoetin alfa DT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - â‰¥ 18 years of age - Receiving hemodialysis or peritoneal dialysis -
        Baseline Hb between 11.0 g/dL and 13.0 g/dL - Currently receiving Epoetin alfa RB ie.
        EPOGEN or PROCRIT - Transferrin saturation (Tsat) &gt;15.0% Exclusion Criteria: - Currently
        receiving or ever received treatment with any erythropoietic stimulating protein other than
        EPOGEN, Procrit and Aranesp. - Uncontrolled hypertension (defined as diastolic blood
        pressure &gt;110 mmHg or systolic BP &gt;180 mmHg during screening). - Grand mal seizure within
        the last 6 months prior to screening. - Acute myocardial ischemia; hospitalization for
        congestive heart failure or myocardial infarction within 12 weeks before enrollment. -
        Stroke (hemorrhagic or ischemic) or transient ischemic attack within 12 weeks before
        enrollment. - Major surgery within 3 months prior to screening (excluding vascular access
        surgery). - Clinical evidence of systemic infection or inflammatory disease at the time of
        screening and up until enrollment.

        For peritoneal dialysis subjects, an episode of peritonitis within 30 days before
        screening. - Known positivity for HIV antibody or Hepatitis B surface antigen.

        Clinical evidence of current malignancy with the exception of basal cell or squamous cell
        carcinoma of the skin. - Blood transfusions within 8 weeks prior to screening or active
        bleeding. - Androgen therapy within 8 weeks prior to screening.

        Systemic hematological disease (eg ,sickle cell anemia, myelodysplastic syndromes,
        hematological malignancy); myeloma; hemolytic anemia. - Other investigational products are
        excluded. - Subject is currently enrolled in, or has not yet completed, a period of at
        least 30 days since ending other investigational device or drug trial(s).

        Psychiatric, addictive, or any other disorder that compromises ability to give truly
        informed consent for participation in this study. - Pregnant or breast feeding (women of
        child-bearing potential must be taking adequate contraceptive precautions). - Anticipating
        or scheduled for a living-related kidney transplant. - Known history of severe
        hyperparathyroidism (PTH &gt;1500pg/ml) within 3 months prior top enrollment. - Currently
        receiving home hemodialysis treatment. - Currently receiving immunosuppressive therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>February 18, 2010</last_update_submitted>
  <last_update_submitted_qc>February 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Epogen</keyword>
  <keyword>Procrit</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Anemia Treatment for Dialysis Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

